China
Africa
Explore chapters and articles related to this topic
Antibody-based Radionuclide Imaging
Published in Michael Ljungberg, Handbook of Nuclear Medicine and Molecular Imaging for Physicists, 2022
Steffie M.B. Peters, Erik H. J. G. Aarntzen, Sandra Heskamp
The first clinical immunoPET study using a 89Zr-labeled antibody study was reported by Börjesson and colleagues. They showed that primary head and neck squamous cell carcinomas (HNSCC) could be detected by PET imaging using 89Zr-labeled chimeric anti-CD44v6 antibody U36 [1]. Since then, several studies have successfully used immunoPET for tumour imaging. One prime example is [89Zr]Zr-DFO-trastuzumab. Dijkers and colleagues have shown that [89Zr]Zr-DFO-trastuzumab PET can detect metastatic liver, lung, bone, and even brain lesions in patients with HER2-positive breast cancer [2]. Furthermore, [89Zr]Zr-DFO-trastuzumab immunoPET supported clinical decision making in patients where HER2 status could not be determined by standard work up. The addition of a [89Zr]Zr-DFO-trastuzumab PET scan to conventional work up changed treatment approach, increased the physicians’ confidence, and improved disease understanding in a subset of patients [9, 39]. In line with this, [89Zr]Zr-DFO-girentuximab PET demonstrated to be of additional value in solving diagnostic dilemmas in patients suspicious for clear cell renal cell carcinoma [8]. Figure 18.2 shows a typical example of a [89Zr]Zr-DFO-girentuximab PET scan
Precision or Personalized Medicine for Cancer Chemotherapy: Is There a Role for Herbal Medicine?
Published in Shaker A. Mousa, Raj Bawa, Gerald F. Audette, The Road from Nanomedicine to Precision Medicine, 2020
Zhijun Wang, Xuefeng Liu, Rebecca Lucinda Ka Yan Ho, Christopher Wai Kei Lam, Moses Sing Sum Chow
A good example is the quantitative proteomics approach for identifying mitochondrial proteins such as ACAT1 and MnSOD for clear cell renal cell carcinoma (ccRCC) [23]. Another example is the identification of eight new potential markers from formalin fixed paraffin embedded biopsy tissues by Metamark Genetics (Cambridge, MA, USA). Their proteomic profile/signature has been found to predict “favorable” versus “non-favorable” pathology of prostate cancer patients independently and may be used as alternatives for clinical decision [22, 24, 25]. Also, the combination of prostate specific antigen (PSA) concentration with β-microseminoprotein (β-MSMB) level which was identified by using MALDI-MS profiling has increased the diagnostic sensitivity [26].
Precision or Personalized Medicine for Cancer Chemotherapy: Is There a Role for Herbal Medicine?
Published in Shaker A. Mousa, Raj Bawa, Gerald F. Audette, The Road from Nanomedicine to Precision Medicine, 2019
Zhijun Wang, Xuefeng Liu, Rebecca Lucinda Ka Yan Ho, Christopher Wai Kei Lam, Moses Sing Sum Chow
A good example is the quantitative proteomics approach for identifying mitochondrial proteins such as ACAT1 and MnSOD for clear cell renal cell carcinoma (ccRCC) [23]. Another example is the identification of eight new potential markers from formalin fixed paraffin embedded biopsy tissues by Metamark Genetics (Cambridge, MA, USA). Their proteomic profile/signature has been found to predict “favorable” versus “non-favorable” pathology of prostate cancer patients independently and may be used as alternatives for clinical decision [22, 24, 25]. Also, the combination of prostate specific antigen (PSA) concentration with β-microseminoprotein (β-MSMB) level which was identified by using MALDI-MS profiling has increased the diagnostic sensitivity [26].
Robust whole-tumour 3D volumetric CT-based radiomics approach for predicting the WHO/ISUP grade of a ccRCC tumour
Published in Computer Methods in Biomechanics and Biomedical Engineering: Imaging & Visualization, 2023
Approximately 140,000 people lose their lives due to kidney cancer each year, and over 330,000 people are newly diagnosed. Renal cell carcinoma (RCC) is among the 10 most common cancer types, and RCC constitutes more than 90% of renal malignancies (Torre et al. 2015; Capitanio and Montorsi 2016). There exist some subtypes of RCC, and the most dominant one is clear cell renal cell carcinoma (ccRCC), with an approximately 75% of occurrence rate (Muglia and Prando 2015).